Core Viewpoint - Genscript Biotech Corporation's stock price increased by approximately 6% following the announcement of the initiation of a Phase I clinical trial for EVM14, a drug aimed at treating squamous non-small cell lung cancer and head and neck squamous cell carcinoma [1] Group 1: Clinical Trial Details - The Phase I study is being conducted by Genscript Biotech's wholly-owned subsidiary, Genscript Biotech (Beijing) Pharmaceutical Technology Co., Ltd., to evaluate the safety, tolerability, and preliminary efficacy of EVM14 in selected patients with solid tumors [1] - The primary objective of the trial is to assess the safety and tolerability of EVM14 in patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma, as well as to determine the recommended Phase II dose (RP2D) [1] - Secondary objectives include evaluating the anti-tumor activity of EVM14, while exploratory objectives involve investigating the correlation between biomarker expression and efficacy, as well as assessing immunogenicity, pharmacokinetics, and anti-drug antibodies [1] Group 2: Drug Information - EVM14 injection is a biopharmaceutical product intended for the treatment of patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma [1] - Squamous non-small cell lung cancer is a common type of lung cancer characterized by symptoms such as cough and hemoptysis, diagnosed through imaging and pathology [1] - Head and neck squamous cell carcinoma typically originates from mucosal surfaces and presents with ulcers and masses, with diagnosis confirmed through pathological examination [1]
云顶新耀盘中涨近6% 附属EVM14注射液启动I期临床 拟适用于鳞状非小细胞肺癌等治疗